Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

The Cleveland Clinic's Taussig Cancer Institute: Patient Experience Reigns Supreme

November 21st 2011

The Cleveland Clinic has long been at the forefront of cutting-edge medicine and research. The center's reputation as a world leader in a multitude of fields, including oncology, is undisputed.

Targeting PI3K/Akt Pathway: 20 Years of Progress

November 21st 2011

This year marks more than 20 years of research into the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway.

Turmeric Ingredient Inhibits Kinase in Cancer Pathway

November 21st 2011

If IKK kinase, a group of inhibitory proteins, activity is not regulated properly, tumors in the body have the ability to migrate and proliferate.

Tumor Angiogenesis: VEGF Pioneer Honored as Quest for Answers Persists

November 18th 2011

The scientific strategy of attacking cancer by thwarting angiogenesis has been on a roller coaster ride for the past 40 years

5 Questions for Josep Tabernero, MD

November 17th 2011

Josep Tabernero, MD, is actively involved in clinical research with molecular targeted therapies, with a focus on EGFR-family and PI3K-Akt-mTOR pathway inhibitors, in phase II and III studies with new chemotherapy agents in gastrointestinal tumors.

A Look at 7 VEGF Inhibitors Currently in Development

November 17th 2011

There are at least 7 drugs specifically targeting VEGF in later-stage clinical trials that have been the subject of presentations at oncology conferences in recent months.

Making Oncology His Path: An Interview With Ezra E.W. Cohen, MD

November 15th 2011

Ezra E. W. Cohen, MD, is a physician and translational researcher at the University of Chicago Medical Center, that focuses on epidermal growth factor receptor (EGFR) inhibitors.

Dr. Goy Explains the Concept of Personalized Medicine

November 4th 2011

Dr. Andre Goy from John Theurer Cancer Center Explains the Concept of Personalized Medicine

Dr. Grimm on the Brain Cancer Predictive Marker MGMT

November 4th 2011

Dr. Sean Grimm from Northwestern University, Feinberg School of Medicine on MGMT as a Predictive Marker in Brain Cancer

Dr. Goldstein on Fulvestrant in Metastatic Breast Cancer

October 26th 2011

Dr. Lori Goldstein from Fox Chase Cancer Center on Fulvestrant in Metastatic Breast Cancer

Guidelines for Genetic Counseling or BRCA 1/2 Testing Are Often Ignored

October 25th 2011

Primary care physicians in the US adhere poorly to established guidelines for genetic counseling and testing for women who are at high risk of breast and ovarian cancer.

Dr. Mills Discusses the Field of Targeted Therapeutics

October 18th 2011

Dr. Gordon B. Mills from the University of Texas MD Anderson Cancer Center Discusses the Field of Targeted Therapeutics

Resistance Strategies in Focus: Combinations Target Multiple Pathways

October 17th 2011

Advances in the understanding of tumor biology and a robust drug development pipeline are combining to form a 'perfect storm' of opportunity for personalized cancer research to make a leap forward.

Dr. Goy Highlights Recent Advances in Oncology

October 14th 2011

Dr. Andre Goy from John Theurer Cancer Center Highlights Recent Advances in Oncology

The Duke Cancer Institute: A Vehicle for Hope

October 14th 2011

For more than 75 years, the cancer programs of Duke University Medical Center in Durham, North Carolina, have been at the forefront of research and patient care.

Dr. Iruela-Arispe on the Dr. Paul Janssen Award Symposium

October 13th 2011

Dr. Luisa Iruela-Arispe from University of California, Los Angeles on the Dr. Paul Janssen Award Symposium

Dr. Scagliotti on the Future of Multiple Gene Profiles

October 12th 2011

Dr. Giorgio Scagliotti from the University of Turin Discusses the Future of Multiple Gene Profiles

Dr. Tripathy Discusses Iniparib Trial Heterogeneity

October 11th 2011

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses Iniparib Trial Heterogeneity

Efforts to Improve HER2 Testing Continue ASCO Panelist Sees Progress

October 11th 2011

Improving the accuracy and value of tumor marker testing in patients with breast cancer has resulted in a dramatic upswing in accredited laboratories and the clarification of guideline definitions.

The Complexities of Inhibiting Angiogenesis Emerge

October 10th 2011

During the past 40 years, the concept of thwarting a tumor by attacking its blood supply has become a central thrust of cancer research, a strategy that reached a milestone with the approval of bevacizumab in 2004.